Q4 Earnings Estimate for Chemours Issued By Zacks Research

The Chemours Company (NYSE:CC) – Research analysts at Zacks Research reduced their Q4 2024 earnings per share estimates for shares of Chemours in a report released on Tuesday, January 14th. Zacks Research analyst R. Department now anticipates that the specialty chemicals company will post earnings per share of $0.10 for the quarter, down from their prior forecast of $0.18. The consensus estimate for Chemours’ current full-year earnings is $1.21 per share. Zacks Research also issued estimates for Chemours’ Q1 2025 earnings at $0.51 EPS, Q4 2025 earnings at $0.16 EPS, FY2025 earnings at $2.01 EPS, Q2 2026 earnings at $0.78 EPS, Q3 2026 earnings at $0.61 EPS, Q4 2026 earnings at $0.42 EPS and FY2026 earnings at $2.43 EPS.

Chemours (NYSE:CC) last released its earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.08. The company had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.44 billion. Chemours had a return on equity of 29.48% and a net margin of 1.34%. Chemours’s quarterly revenue was up .9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.64 earnings per share.

CC has been the topic of several other research reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $25.00 price target on shares of Chemours in a report on Thursday, December 12th. Barclays upped their target price on shares of Chemours from $21.00 to $23.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Morgan Stanley decreased their price target on Chemours from $25.00 to $22.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. BMO Capital Markets upped their price objective on Chemours from $30.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, October 7th. Finally, Mizuho decreased their target price on Chemours from $22.00 to $21.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 7th. Five analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $23.75.

Chemours Stock Up 1.7 %

CC stock opened at $19.41 on Thursday. The business’s 50-day moving average price is $19.13 and its 200-day moving average price is $19.77. The stock has a market cap of $2.90 billion, a P/E ratio of 38.82 and a beta of 1.83. The company has a quick ratio of 0.92, a current ratio of 1.73 and a debt-to-equity ratio of 6.05. Chemours has a twelve month low of $15.10 and a twelve month high of $32.48.

Institutional Trading of Chemours

Hedge funds have recently made changes to their positions in the business. Quantbot Technologies LP increased its stake in Chemours by 119.6% during the second quarter. Quantbot Technologies LP now owns 122,973 shares of the specialty chemicals company’s stock worth $2,776,000 after acquiring an additional 66,966 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in Chemours during the 2nd quarter valued at $2,480,000. Vanguard Personalized Indexing Management LLC lifted its position in Chemours by 14.7% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 14,102 shares of the specialty chemicals company’s stock worth $318,000 after buying an additional 1,803 shares during the last quarter. Seven Eight Capital LP purchased a new position in Chemours during the second quarter worth $2,657,000. Finally, XTX Topco Ltd increased its position in Chemours by 122.2% during the second quarter. XTX Topco Ltd now owns 26,794 shares of the specialty chemicals company’s stock valued at $605,000 after acquiring an additional 14,735 shares during the last quarter. 76.26% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, SVP Alvenia Scarborough sold 7,500 shares of the company’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $20.64, for a total transaction of $154,800.00. Following the sale, the senior vice president now owns 16,645 shares of the company’s stock, valued at $343,552.80. This represents a 31.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.47% of the stock is owned by company insiders.

Chemours Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, December 16th. Investors of record on Friday, November 15th were given a $0.25 dividend. The ex-dividend date was Friday, November 15th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 5.15%. Chemours’s dividend payout ratio is currently 200.00%.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.